Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Adaptimmune Therapeutics PLC (ADAPY) vs Vyome Holdings, Inc. (HIND)

Adaptimmune Therapeutics PLC and Vyome Holdings, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Vyome Holdings, Inc. are of similar size ($14.6M and $14.5M). Adaptimmune Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Vyome Holdings, Inc. trades at 0.0×. Vyome Holdings, Inc. grew revenue faster over the last twelve months: 103.8% against −54.0%. Adaptimmune Therapeutics PLC has the higher net margin (−262.5% vs −8,711.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Adaptimmune Therapeutics PLC leads on 11 and Vyome Holdings, Inc. on 5.

Valuation

Metric ADAPY HIND Biotechnology median
P/E n/m 0.00 7.88
P/S 0.12 110.31 11.47
P/B n/m 1.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.12 78.55 10.73
Earnings yield (2,166.67%) 74,921.03% (28.84%)
Free cash flow yield (2,380.45%) (38.96%) (23.03%)

Profitability

Metric ADAPY HIND Biotechnology median
Gross margin 94.81% 52.77% 65.16%
Operating margin (427.75%) (9,184.82%) 0.00%
Net margin (262.46%) (8,711.71%) 0.00%
Free cash flow margin (288.20%) (4,298.00%) 0.00%
Return on equity (1,349.52%) (172.10%) (57.72%)
Return on assets 0.00% (124.23%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY HIND Biotechnology median
Revenue growth (TTM) (53.99%) 103.81% 5.64%
EPS growth (last fiscal year) 142.86% 99.92% —
Revenue growth, 5-year CAGR 8.40% (50.98%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY HIND Biotechnology median
Debt to equity (0.36) 0.00 0.00
Current ratio 1.52 4.37 4.73
Net debt to EBITDA 0.47 0.48 0.96

Dividend

Metric ADAPY HIND Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADAPY HIND Biotechnology median
Market cap 14.55m 14.46m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack